＜シンポジウム（2）―11―1＞アルツハイマー病の新展開―分子病態から治療戦略へ
Nピログルタミル化したアミロイドの病的メカニズムとピログルタミル化酵素阻害薬による治療の可能性
岩田 修永, 浅井 将
長崎大学大学院医歯薬学総合研究科分子創薬科学講座〔〒852―8521 長崎市文教町1―14〕
Aggregation and accumulation of amyloid-β peptide (Aβ) in the brain are triggering events leading to the pathological cascade of Alzheimer's disease (AD). Aβ accumulates in AD brains and forms amyloid plaques, which consist mostly of amino-terminally truncated and/or modified Aβs, among which Aβ3pyroglutamate (Aβ3pE) is a major product. Thus, the N-terminal structures of accumulated species of Aβ are different from those secreted from neurons. Aβ3pE-42 is more hydrophobic, more easily self-aggregated (250-fold), and is more resistant to proteolytic degradation (4-fold) than Aβ1-42. Therefore, Aβ3pE appears to act as a seed for the formation of oligomers and amyloid plaques. Aβ is physiologically degraded via the neprilysin-mediated pathway in the brain. However, if neprilysin activity is low, a compensatory metabolic pathway is up-regulated, in which exopeptidases, such as aminopeptidase or dipeptidyl peptidase, and glutaminyl cyclase (QC) may be involved, generating Aβ3pE. It is reported that QC is up-regulated with AD development. Recent study revealed that administration of synthetic QC inhibitor reduced total amyloid burden in the brains of APP transgenic mice (Tg2576) via inhibition of Aβ3pE production and also alleviated impaired cognitive function. Thus, inhibition of Aβ3pE formation appears to be a novel target for therapy and prevention of AD.
Full Text of this Article in Japanese PDF (201K)
(臨床神経, 52：1162−1164, 2012)
key words：アルツハイマー病，アミロイドβペプチド，ピログルタミル化，グルタミニルシクラーゼ，ピログルAβ
（受付日：2012年5月24日）
